Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Highlight
  • Published:

Haematological cancer

ASPIRE for unprecedented benefit with carfilzomib in MM

Nature Reviews Clinical Oncology volume 12, page 65 (2015)Cite this article

Subjects

Access through your institution
Buy or subscribe

Many advances in the treatment of multiple myeloma (MM) have been made in recent years. In particular, the efficacy of lenalidomide plus dexamethasone therapy until disease progression has been recognized, and this regimen has become a reference treatment for this disease. Nevertheless, relapse remains a considerable challenge. Carfilzomib, a proteasome inhibitor, has shown promise in this setting, both as a monotherapy and combined with lenalidomide–dexamethasone. Now, the phase III ASPIRE trial has further demonstrated the efficacy of the triple drug regimen in relapsed MM.

...PFS in patients with MM has not been prolonged to this extent by any other regimen

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Stewart, A. K. et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 10.1056/NEJMoa1411321

Download references

Authors
  1. David Killock
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Killock, D. ASPIRE for unprecedented benefit with carfilzomib in MM. Nat Rev Clin Oncol 12, 65 (2015). https://doi.org/10.1038/nrclinonc.2014.228

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrclinonc.2014.228

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing